Introduction
A number of debilitating skin diseases, especially those caused by inherited single gene mutations, are candidates for gene therapy. As these diseases are life-long disorders, any gene-based therapy will require long-term expression of the corrective gene. 1, 2 Despite advances in gene transfer methodologies, a major issue for long-term expression is the potential for host responses against the cells expressing the therapeutic gene product, especially if the disease causing mutation results in no protein or a truncated protein. [2] [3] [4] The first report of a successful trial in humans was for junctional epidermolysis bullosa and used autologous, genetically modified keratinocytes. 5 In this instance, the disease causing mutation was both a null and a point mutation in the LAMB3 gene resulting in a deficiency of laminin-5. Fortunately, no immune responses were reported to the gene-altered cells 1 year after gene transfer mainly because of the patient's compound mutation allowed residual synthesis making the patient tolerant to transgene product. 5 Nevertheless, host responses to neoantigen production are likely to become central issues in future trials for this and other genodermatoses. In this study, we report on differential host responses to neoantigen production depending on whether the gene-altered cells are keratinocytes or fibroblasts.
The nature of host responses in gene therapy depends on various factors including the immunogenicity of the transgene product, the method of gene transfer and the type of cell or tissue producing the gene product. 6, 7 To study host responses specifically in the case of cutaneous gene therapy, we have developed models for both ex vivo and in vivo transduction of skin in immunocompetent mice. 8, 9 Direct retroviral-mediated gene transfer to epidermis (in vivo method) or orthotopic transplantation of ex vivo-transduced keratinocytes to transgene-tolerant mice results in long-term transgene expression in epidermis. In non-tolerant mice, however, transgenespecific responses lead to rejection of the genetically modified keratinocytes regardless of the method of gene delivery. 8, 9 Although transduced cells are rejected acutely whether the method of gene delivery is ex vivo or in vivo, the mechanism of immune rejection seems to differ depending on whether an ex vivo or an in vivo method of gene transfer was used. The loss of transgene expression after direct gene transfer to mouse skin is associated with Th1-type responses, whereas implantation of ex vivo-transduced keratinocytes expressing an intracellular antigen induces a Th2-biased response. This Th2 response is highlighted by an increased secretion of IL-4 and IL-5 by T lymphocytes and infiltration of mixed infiltrates including numerous eosinophils into the transduced skin. 10 Keratinocytes are known to express a wide variety of soluble mediators of inflammation that regulate immune responses by influencing multiple different resident cell types including macrophages, dendritic cells (DC), neutrophils, lymphocytes, eosinophils and mast cells. 11 Whether Th2/allergic inflammatory responses to antigenic transgene expression in keratinocytes are specific to this cell population or to the skin microenvironment, or are a characteristic of the ex vivo gene transfer is not clear.
Both fibroblasts and keratinocytes are potential targets for therapeutic gene transfer depending on the nature of the disease. In instances such as correction of dystrophic epidermolysis bullosa when either fibroblasts or keratinocytes could be modified to supply therapeutic protein, fibroblasts have been proven to be the preferred target over keratinocytes, as the gene-corrected fibroblasts supplied higher amount of collagen VII to the basement membrane than the gene-corrected keratinocytes. 12 Although the nature of host responses to genetically modified fibroblasts has not been studied in detail, the known differences in susceptibility of dermal and epidermal allografts to rejection after transplantation suggest key differences between the immunogenic profiles of keratinocytes and fibroblasts. [13] [14] [15] [16] Unlike keratinocytes, fibroblasts have long been considered to be minimally immunogenic. 17, 18 In vitro data support immunosuppressive effects of dermal fibroblasts on allogenic T-cell proliferation, 19 although the immunoregulatory effects of fibroblasts in vivo are more controversial. Some studies have reported that allogeneic fibroblasts are accepted across the histocompatibility barriers after transplantation, 15, 16, 20 whereas others have shown that fibroblasts sensitize the host to alloantigens or secreted antigens. 17, [21] [22] [23] [24] To compare host responses to transgene expression in fibroblasts and keratinocytes independent of antigen levels, gene transfer technique or transplantation method, we used an orthotopic murine skin transplantation method in which a mixture of keratinocytes and fibroblasts are implanted onto an excised wound bed on the back of a syngeneic mouse to regenerate skin. 9 We used enhanced green fluorescent protein (GFP) as a model antigen and targeted expression to either keratinocytes or fibroblasts. In this way, we were able to analyze transgene-specific immune responses as well as the fate of the transgenic cells. Our studies showed that, although transgene targeted to either cell population induced transgene-specific responses, the nature of these immune responses and the kinetics of immune rejection were significantly different for these two cell types.
Results

Analysis of transgene expression in fibroblasts and keratinocytes before and after transplantation
To obtain comparable levels of transgene expression in keratinocytes and fibroblasts, GFP-expressing cells were isolated from FVB-Nagy-GFP mice in which expression of GFP is controlled by actin promoter and therefore is expressed in all nucleated cells. 25 Analysis of GFP expression in cultured fibroblasts and keratinocytes by western blot (Figure 1a ) and flow cytometry ( Figure 1b ) verified comparable levels of expression.
We have earlier shown that epidermal cells maintained for more than 5 days in culture were completely depleted of antigen-presenting cells (APCs), thereby reducing the possibility of direct antigen presentation by transplanted GFP-expressing APCs. 9 There are resident populations of APCs in dermis including macrophages and dermal DCs. To examine the levels of contaminating APCs in cultures established from dermal cells, levels of CD11c transcript, a monocyte/DC-specific marker, were analyzed in primary and secondary cultures of dermal fibroblasts by reverse transcriptase-PCR. As shown in Figure 1c , significant levels of CD11c Immune responses in cutaneous gene therapy Z Zhang et al transcripts were detected in primary cultures of fibroblasts ( Figure 1c , P0), confirming contamination of dermal preparations with APCs. However, CD11c transcript levels dropped precipitously to undetectable levels after passaging ( Figure 1c , P1 and P2), indicating a progressive loss of APCs in culture. Therefore, to limit GFP expression to fibroblasts and avoid direct antigen presentation by APCs, cells recovered from mouse dermis were cultured and passaged twice before transplantation.
Earlier, we had shown that primary cultures of dermal fibroblasts support skin reconstitution in orthotopic transplants. To determine whether cultured fibroblasts maintain that capacity, GFP-expressing fibroblasts (FB-GFP) were mixed with non-transgenic isogenic keratinocytes (H-2 q ) and used to reconstitute skin on GFP-tolerant mice (Gad-GFP, H-2 q ) in which GFP is expressed in brain but not in skin. 9, 26 In some animals, GFP-expressing keratinocytes (KC-GFP) were mixed with non-labeled isogenic fibroblasts and implanted onto GFP-tolerant mice as described earlier. 9 Skin grafts were examined weekly for surface GFP expression using a fluorescent stereoscope. As shown in Figure 1d , cultured transgenic fibroblasts contributed to skin formation by repopulating the dermal compartment of the regenerated skin. Surface GFP was detected whether GFP was targeted to keratinocytes or fibroblasts (Figure 1d , top panels), although the signal from KC-GFP was brighter because of the relative position and cell density in the epidermis. Analysis of tissue sections obtained at 6 weeks after transplantation by fluorescent microscopy showed that cultured fibroblasts survived in vivo, contributed to the formation of dermis, and did not migrate beyond the graft boundaries ( Figure 1d ). Moreover, GFP expression persisted for the entire observation period of 20 weeks (Figure 2 ), indicating that stable and long-term engraftment of genetically modified fibroblasts is achievable in the absence of transgene-specific immune response.
Fate of antigen-expressing fibroblasts and keratinocytes in immunocompetent mice
To determine the fate of dermal fibroblasts expressing an antigen, FB-GFP were mixed with syngeneic nonlabeled keratinocytes and used to reconstitute skin on the back of adult FVB mice (H-2 q ) or Gad-GFP mice. For a comparison, KC-GFP were mixed with non-labeled fibroblasts and implanted onto FVB mice as described above. Skin grafts were examined weekly for surface GFP expression and clinical signs of graft rejection. Analysis of surface GFP in tolerant mice showed continued GFP expression in all the grafted mice for the entire period of observation with no reduction in GFP levels or graft size (Figure 2 and Supplementary Figure S1 ). As expected, FVB mice grafted with KC-GFP showed progressive loss of surface GFP starting at 3 weeks after grafting with a complete loss of grafted skin in 4-5 weeks after grafting ( Figure 2 ). The loss of surface GFP in this group was accompanied by clinical signs of acute graft rejection, including inflammation, erythema, contracture, necrosis and hair loss ( Figure 4m ). In mice grafted with FB-GFP, however, there was a significant variation in the kinetics of GFP loss ( Figure 2 ). In 25% of grafted mice (n ¼ 5), surface GFP was lost at week 3 after grafting with no obvious change in the appearance of grafted skin (Supplementary Figure S1 ). In the remaining animals (n ¼ 15), transgenic fibroblasts failed to induce acute rejection and surface GFP continued to be detected for at least 7 weeks. In these animals GFP was lost either between 7-10 weeks after grafting (n ¼ 11), or persisted for the entire observation period of 20 weeks (n ¼ 4) ( Figure 2 ), suggesting long-term engraftment of transgenic fibroblasts in a small number of animals. The chronic loss of transgenic fibroblasts in the majority of skin grafts in normal, but not in GFP-tolerant, mice suggests immune-mediated clearance of transgenic fibroblasts, although the slow kinetics of rejection suggests that a different type of immune response was responsible for rejection of keratinocytes.
Analysis of antigen-specific immune responses to transgenic fibroblasts and keratinocytes
To characterize host immune responses to antigen expressed in fibroblasts, GFP-specific immune responses were analyzed in mice grafted with FB-GFP and compared with those induced against KC-GFP. ELISA (enzyme-linked immunosorbent assay) analysis of sera collected at 4, 6 or 10 weeks after grafting for anti-GFP immunoglobulin G (IgG) showed substantial quantities of GFP-specific antibodies at 4 weeks after transplantation with a steady increase in antibody titers in all FVB mice grafted with FB-GFP, regardless of the kinetics of GFP loss (Figure 3a ). Antibody titers, however, were significantly lower (about three fold) in mice grafted with transgenic fibroblasts as compared with those grafted with KC-GFP ( Figure 3a ).
To analyze cell-mediated responses, splenocytes were isolated from mice grafted with FB-GFP or KC-GFP and T-cell proliferative responses to GFP were assessed in a mixed lymphocyte reaction. As shown in Figure 3b , there was a significant increase in proliferation of T cells from FVB mice grafted with either KC-GFP or FB-GFP, but not those isolated from grafted GFP-tolerant mice. These data indicate that expression of an intracellular antigen 
Histological analysis of skin grafts containing transgenic keratinocytes or fibroblasts
The local inflammatory responses to antigen expression by either fibroblasts or keratinocytes were examined in histological skin samples obtained at 4 weeks after grafting. The results indicate substantial differences in tissue architecture, as well as in intensity and type of inflammatory cells between the two cell types (Figures 4i and o). Rejection of KC-GFP grafts was accompanied by a mixed inflammatory infiltrates, epidermal hyperplasia and loss of hair follicle integrity and tissue architecture (Figure 4o ). In contrast, skin containing FB-GFP showed a mildly hyperplastic epidermis. Hair follicles were intact despite significant inflammatory infiltrates around the follicles and dermal papilla (Figure 4i ). The infiltrating cells included CD4+ cells, CD8+ T cells, and macrophages, and were present in all FVB mice grafted with FB-GFP including those which failed to exhibit acute rejection (Figures 4g-l) . This infiltrate, however, was specific to antigen expression (that is, GFP) as it was completely absent from grafts of Gad-GFP mice in which GFP is not an antigen (Figures 4c-f ). In these mice, the number and distribution of inflammatory cells were comparable to that of the normal skin (Figures 4c-f ). Comparative analysis of inflammatory cells infiltrating skin grafts containing transgenic fibroblasts or keratinocytes showed a comparable number of CD4+ and CD8+ T cells, but a significant reduction in the numbers of macrophages and B cells, and a complete lack of eosinophilic infiltrates when GFP was targeted to fibroblasts rather than keratinocytes (Table 1 ). These data indicate that expression of a single antigen in either fibroblasts or keratinocytes initiates an inflammatory reaction, but recruits different types of immune cells to the site of transgene expression.
Tissue responses to antigenic transgene expression targeted to keratinocytes or fibroblasts
Significant differences in the histopathology of skin grafts containing antigenic fibroblasts or keratinocytes suggest different types of immune responses mediating rejection of transgenic cells. To further evaluate tissue immune responses, transcript levels of several cytokines including IFN-g and TNF-a (Th1 cytokines), IL-4 and thymic stromal lymphopoietin (TSLP) (Th2 cytokines), and TGF-b (Treg cytokine) were evaluated in the grafted tissue samples by quantitative reverse transcriptase-PCR. GFP-expressing grafts of GFP-tolerant mice served as controls. As shown in Figure 5 , significant levels of Th1 cytokines, IFN-g and TNF-a were detected in the grafts whether antigen was targeted to keratinocytes or fibroblasts, although IFN-g levels were significantly higher in the latter, indicating a dominant Th1 response to antigenexpressing fibroblasts. Expression of Th2 cytokines, IL-4 and TSLP, was restricted to FVB mice grafted with KC-GFP, consistent with a dominant Th2 responses/ allergic inflammatory responses. 10 TGF-b, which is expressed by regulatory T cells and plays an immunosuppressive role, 27 was significantly suppressed in grafted skin of FVB mice containing either KC-GFP or FB-GFP when compared with the grafted skin of GFPtolerant mice. These data indicate that the majority of T cells infiltrating the grafted keratinocytes or fibroblasts are activated effector T cells. Despite a distinct Th1 polarized responses to transgenic fibroblasts, these cells survive acute rejection. Furthermore, Th2 type responses are induced only to antigen expression in keratinocytes.
In vitro studies have shown that dermal fibroblasts inhibit allogenic T-cell activation at least partly through IFN-g-mediated induction of indolamine 2,3-deoxygenase (IDO) in fibroblasts. 19 Therefore, chronic rejection of fibroblasts may be related to IFN-g-mediated induction Figure 3 Immune activation in FVB mice grafted with transgenic fibroblasts expressing an antigen. (a) Sera were collected at 4, 6 or 10 weeks after grafting and assessed for the presence of anti-green fluorescent protein (GFP) immunoglobulin G (IgG) by ELISA using a monoclonal anti-GFP antibody as a standard. Error bar represent s.e. Po0.005 for GFP-expressing keratinocytes (KC-GFP) and GFP-expressing fibroblasts (FB-GFP) grafted FVB mice (n ¼ 10). (b) GFP-specific lymphocyte proliferation at 4 weeks after grafting. Splenocytes were isolated from grafted mice and cultured for 72 h with mitomycin-treated GFP-expressing splenocytes or mock splenocytes. Lymphocyte proliferation was determined by measurement of 3 H-thymidine incorporation during the last 16 h of culture (n ¼ 3 per group). Error bar represent s.e. Po0.05 for GFP-stimulated and mock-stimulated.
Immune responses in cutaneous gene therapy Z Zhang et al of IDO in transgenic fibroblasts. However, analysis of the grafted tissue samples for IDO transcript levels showed that despite the higher levels of IFN-g in skin grafts containing FB-GFP, IDO expression was comparable to that of control grafts and was significantly lower than that of KC-GFP grafts ( Figure 5 ). IFN-g-induced expression of IDO in human keratinocytes in the skin lesions of patients with atopic dermatitis or psoriasis have also been reported and may function as a feedback mechanism to control inflammation. 28 
Discussion
Using a model of ex vivo cutaneous gene therapy, we compared immune responses with an antigenic transgene product expressed in two major skin cell types, fibroblasts and keratinocytes, and noted distinct immunogenic profiles. Expression of an intracellular antigen in either fibroblasts or keratinocytes was sufficient to prime T cells and to induce antigen-specific responses. However, there was a significant difference in the nature of these responses and the kinetics of transgene loss. Transgenic keratinocytes were rejected relatively rapidly by a dominant Th2 inflammatory response, whereas transgenic fibroblasts induced a dominant Th1 type inflammation in the graft. Therefore, the induction of Th2/allergic inflammation to antigenic transgene expression is unique to keratinocytes not to the method of gene transfer or transplantation. Summary of distribution of inflammatory cells in skin reconstituted from transgenic fibroblasts (FB-GFP) or keratinocytes (KC-GFP) on FVB mice or from transgenic fibroblasts on GFP-tolerant mice (Gad-GFP). Cellular infiltrates were assessed in five randomly selected fields at Â 400 magnification and are expressed as Mean±s.e.m. 
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The dose of antigen is a determinant of the Th1/Th2 decision, with high doses inducing Th1 polarization and low doses inducing Th2 polarization. 29 However, the observed differences in host responses to fibroblasts and keratinocytes could not be simply explained by antigen dose, as the same number of fibroblasts and keratinocytes were implanted and GFP levels were comparable or even slightly higher in keratinocytes (Figure 1 ). Moreover, our earlier studies with keratinocytes in which transgene expression was controlled by a cellular promoter and there was a sixfold difference in antigen expression levels, or when only a fraction of keratinocytes (10-20%) were transduced, did not show a significant impact on the intensity and type of transgenespecific host response. 10 Our experimental model was designed to examine host responses to an intracellular transgene product. Whether similar Th1/Th2 polarization occurs when either a membrane-associated antigen or a secreted antigen is expressed by fibroblasts or keratinocytes remains to be determined. The sub-cellular localization of expressed protein has been shown to influence the nature of the induced immune responses in DNA immunization. 30, 31 However, direct gene transfer results in transfection of APCs and differential processing of cell-associated and secreted proteins. 32, 30 In the absence of direct presentation of antigenic transgene by donor APCs in our transplantation model, T-cell priming and activation is likely mediated by cross-presentation of antigen released from either fibroblasts or keratinocytes to the host APCs. 33 It is clear that some DC subsets bias Th1/Th2 polarization. As skin contains numerous APCs including Langerhans cells, dermal DC and macrophages, the uptake and processing of antigen from keratinocytes and fibroblasts by different subset of APCs may explain the polarization of immune responses elicited to antigen expression by these two cell types. [34] [35] [36] Among cells that drive Th2 differentiation are TSLP-activated DCs. 37 TSLP represents a key keratinocyte-derived cytokine that creates a Th2permissive microenvironment and directly triggers DC-mediated allergic inflammation. [37] [38] [39] The specific upregulation of TSLP transcript in skin grafts containing antigenic keratinocytes may explain induction of Th2-polarized responses to antigen expression in keratinocytes but not in fibroblasts.
The extensive tissue damage associated with rejection of transgenic keratinocytes was not observed during rejection of transgenic fibroblasts, even in the small number of mice in which transgenic fibroblasts were rejected acutely in week 3-4 after grafting (Supplementary Figure S1 ). The extensive tissue damage associated with the rejection of transgenic keratinocytes is a hallmark of Th2 responses. Th2 lymphocytes produce cytokines such as IL-4 and IL-5 that promote eosinophil infiltration and degranulation. 29 Eosinophils exert cytotoxic activity through the release of several molecules such as leukotriene, superoxides, major basic protein and eosinophil cationic protein that mediate tissue destruction. 40 Noteworthy we have earlier shown that suppression of eosinophilic infiltrates in mice grafted with transgenic keratinocytes results in suppressed tissue destruction and delayed rejection of transgenic keratinocytes suggesting a key role for eosinophils in acute rejection of transgenic keratinocytes. 10 The majority of mice transplanted with antigenic fibroblasts failed to induce acute rejection, although a significant number of CD4+ cells, CD8+ T cells and macrophages infiltrated the regenerated dermis. In these mice, rejection of fibroblasts followed a slow kinetics over a period of 7-10 weeks after grafting and in about 20% of grafted animals, transgenic fibroblasts persisted for the entire observation period of 20 weeks. There was no correlation, however, between the induction of immune responses (using antibody responses as an indicator) and long-term survival of transgenic fibroblasts. Although, histological analysis of grafted tissue surviving after 20 weeks showed no significant inflammatory infiltrates, these animals showed sustained and high levels of serum anti-GFP IgG comparable to cohort mice in which grafts were lost (data not shown).
Considering that intense inflammatory infiltrates were present in all the grafts analyzed at 4 weeks after grafting (n ¼ 5), it is likely that initial tissue infiltrates were present in surviving grafts but were cleared at a later time. Although the mechanism of survival of fibroblasts in some animals remains to be investigated, the inability of mice with long-term surviving grafts to accept second grafts of KC-GFP argues against induction of antigenspecific tolerance (data not shown). Furthermore, the lack of a significant difference in intragraft IDO, TGFb, IL10 and FoxP3 transcript levels between keratinocytes and fibroblast grafts at 4 weeks after grafting does not support a role for Treg cells in suppressing immune responses to antigen expression in fibroblasts ( Figure 5 and data not shown). Similar results were seen when fibroblasts expressing human FIX were implanted subcutaneously in rabbits. In this study 2 out of 15 animals showed long-term expression of transgene despite measurable titers of FIX-specific antibodies. 22 Whether this is the result of active immune suppression, ignorance or inefficient killing of fibroblasts needs further investigation.
In conclusion, our studies have shown that despite the low immunogenic profile of fibroblasts, antigen targeted to these cells could prime T cells and induce humoral and cellular immune responses, although the nature of these responses was different from those induced to keratinocytes. Our data suggest that different strategies will be required to modulate or control destructive immune responses in gene therapy targeted to different cell types in a tissue.
Materials and methods
Animals, cells and skin transplantation FVB/NJ, FVB-GadGFP and FVB-GFPNagy transgenic lines were purchased from the Jackson Laboratories (Bar Harbor, MA, USA). All strains of mice used for transplantation were male and between 6 to 8 weeks of age. Animal studies were conducted in accordance with the institutional guidelines set forth by the State University of New York. Epidermal and dermal cells were prepared from 1-2-day-old mouse skin using standard procedures. 9 Epidermal cells were seeded on collagen coated plates in keratinocyte-serum free media (Invitrogen, Grand Island, NY, USA) containing 0.3 mM calcium for 6 h to allow attachment, then the media was changed to 0.05 mM calcium to allow optimum condition Immune responses in cutaneous gene therapy Z Zhang et al for cell proliferation. After 5-7 days, keratinocytes were harvested for transplantation. Dermal cells were cultured in DME containing 10% fetal bovine serum and passages twice before harvested for transplantation.
For transplantation, 4 Â 10 6 cultured epidermal cells were mixed with 4 Â 10 6 cultured dermal fibroblasts (isolated either from FVB or Nagy-GFP mice) and implanted as a slurry (150 ml volume) onto the fascia but under a silicon chamber implanted onto the back of an anesthetized mouse. 9 After 1 week, chambers were removed and wounds were allowed to heal. A welldeveloped skin appeared 7-10 days thereafter.
Detection of GFP expression in skin
Green fluorescent protein expression in cultured cells was determined either by flow cytometry using a FACSCaliber (BD Immunocytometry System, San Diago, CA, USA) or by western analysis. Equal amounts (40 mg) of total keratinocyte and fibroblast lysates were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, probed with a polyclonal anti-GFP antibody (Clontech, Mountain View, CA, USA) and developed with chemiluminescent detection system (ECL kit, Amersham Biosciences, Piscataway, NJ, USA). As a control, 25 ng of recombinant GFP was included in the western analysis.
To assess GFP expression in grafted skin of live animals, animals were anesthetized and placed under a fluorescent stereoscope (Bio 2M, Zeiss Inc., Thornwood, NY, USA) equipped with a mercury lamp and wide band filter set for GFP. Images were captured using a Nikon Coolpix 995 (Nikon Instrument Inc. Melville, NY, USA) and processed using Adobe Photoshop. For detection of GFP expression in tissue sections, samples were fixed in cold 4% paraformaldehyde for 30 min before embedding in OCT. Frozen sections were dried and rehydrated, mounted in Vectashield mounting media with 4',6-Diamidino-2-phenylindole (DAPI) (Vector Laboratories, Inc. Burlingame, CA, USA), examined and photographed with an epifluorescent Eclipse 800 microscope (Nikon Instrument Inc.) equipped with image analyzing software.
Immunofluorescent analysis
Cryosections were rinsed with phosphate-buffered solution, dried and fixed with cold acetone for 2 min. Fixed tissue sections were blocked in 5% non-fat milk in phosphate-buffered solution and stained with 1 mg ml À1 of rat anti-mouse CD4, CD8a, B220 and F4/80 monoclonal antibodies (BD-Pharmingen, San Diego, CA, USA) for 60 min. Antibodies were detected using the Alexa 594-conjugated goat anti-rat antibody (Molecular Probes, Eugene, OR, USA). Cellular infiltrates were assessed in five randomly selected fields at Â 400 magnification.
Analysis of GFP-specific responses in grafted mice
Antibody responses to GFP were determined by ELISA as described earlier 10 To determine GFP-specific lymphocyte proliferation, splenocytes were incubated in 96-well plates (triplicates, 2 Â 10 5 cells per well) for 72 h with an equal number of mitomycin-treated GFP-labeled or non-labeled splenocytes. Cells were pulsed with 1 mCi 3 H-thymidine per well for the last 16 h and harvested using a semi-automatic harvester (Skatron Instrument, Lier, Norway). Thymidine uptake was measured with a scintillation counter (LKB-Wallac, Gaithersburg, MD, USA).
RNA analysis
For detection of low levels of contaminating APCs in culture, total RNA was isolated from primary and secondary cultures of fibroblasts using Trizol reagent (Gibco/BRL, Grand Island, NY, USA). RNA samples (0.2 ug) were analyzed by reverse transcriptase-PCR (OneStep RT-PCR kit, Qiagen, Hilden, Germany) using primers specific to cd11c gene, a marker for DCs. 9Pgk-1 primers were used as controls to ensure RNA integrity and equal loading. PCR products were analyzed by 1% agarose electrophoresis with ethidium bromide staining. Relative quantification of cytokine mRNA expression in RNA isolated from skin biopsies was carried out by quantitative real-time PCR using a 7300 Real Time System (Applied Biosystem, Foster City, CA, USA). The PCR reaction was run with Syber green Taq polymerase for 45 cycles of: 95 1C, 15 s and 60 1C, 1 min. All the samples were run in triplicate and non-template controls were included in each run. The RNA levels of the target genes were normalized against Pgk-1 transcript levels and the comparative C T ð2 ÀDDCT Þ method 41 was used for calculating relative cytokine mRNA expression. The PCR efficiencies, as determined by assaying serial dilutions of RNA, were approximately equal for the target genes and the housekeeping genes.
